The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Bispecific antibodies in multiple myeloma: their current role and the future
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, provides an overview of the role of bispecific antibodies in the treatment of multiple myeloma (MM). Currently, teclistamab and elranatamab are approved for relapsed/refractory (R/R) cases, showing promising responses in achieving measurable residual disease (MRD) negativity, albeit with some tolerability concerns. Dr Cerchione underscores the potential for bispecifics in frontline therapy or for smoldering myeloma treatment, targeting novel antigens, and the importance of sequencing these agents effectively within treatment regimens. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
